Company Analysis
Sign in

Moleculin Biotech, Inc. (MBRX)

Nasdaq: MBRX · Pharmaceutical Preparations · Houston, TX · filing with the SEC since 2015
Full chart Alerts Compare
Grade5.1
◀ Past 6.3● Present 4.8▶ Future 4.5
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

4 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Moleculin Biotech, Inc.’s names, not what it holds today.

Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and none in 2023
Applications published
5
since 2001, to Dec 31, 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Moleculin Biotech, Inc. its own name
US, as the owner printed on each patent
4 granted
1 published
Moleculin Biotech, Inc. its own name
named as the applicant on its applications, in US
0 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 25, 202512,257,262Method of reconstituting liposomal annamycinPharmaceuticalsMoleculin Biotech, Inc.
Mar 25, 202512,257,261Preparation of preliposomal Annamycin lyophilizatePharmaceuticalsMoleculin Biotech, Inc.
May 14, 202411,980,634Method of reconstituting liposomal annamycinPharmaceuticalsMoleculin Biotech, Inc.
Apr 9, 202411,951,118Preparation of preliposomal annamycin lyophilizatePharmaceuticalsMoleculin Biotech, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Feb 8, 20242024/0041909PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATEPharmaceuticalsMoleculin Biotech, Inc. · patent 11,951,118 granted from it
Jan 25, 20242024/0024345METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCINPharmaceuticalsMoleculin Biotech, Inc. · patent 11,980,634 granted from it
Apr 27, 20232023/0130134METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOFPharmaceuticalsMoleculin Biotech, Inc.
Apr 7, 20222022/0105116METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCINPharmaceuticalsMoleculin Biotech, Inc. · patent 12,257,262 granted from it
Apr 7, 20222022/0105115PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATEPharmaceuticalsMoleculin Biotech, Inc. · patent 12,257,261 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MBRX · research, not advice